The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept

Chinese Journal of Ophthalmology

Volumn 46, Issue 2, 2010, Pages 145-150

  Zhang, Mei Fen ^a   Zhao, Chan ^a   Wen, Xin ^a   Du, Hong ^a   Zhao, Yan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Behcet syndrome; Tumor necrosis factor; Uveitis

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; FEMALE; HUMAN; MALE; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UVEITIS; BEHCET SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 77956521636     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.04124081.2010.02.011     Document Type: Article

References (19)

1. Krause I, Weinberger A. Behcet's disease. Curr Opin Rheumatol, 2008, 20:82-87.
2. Yates PA, Michelson JB. Behcet disease. Int Ophthalmol Clin, 2006, 46:209-233.
3. Bonfioli AA, Orefice F. Behcet's disease. Semin Ophthalmol, 2005,20:199-206.
4. Kaklamani VG, Kaklamanis PG. Treatment of Behcet's diseasean update. Semin Arthritis Rheum, 2001, 30:299-312.
5. Munoz-Femandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panu vein's in Behcet' s disease. Lancet, 2001, 358:1644. (Pubitemid 33101925)
6. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet' s disease. Lancet, 2001, 358 : 295-296. (Pubitemid 32738970)
7. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology, 2007, 46: 736-741. (Pubitemid 47061701)
8. Criteria for diagnosis of Behcet's disease. International study group for Behcet's disease. Lancet, 1990, 335: 1078-1080.
9. Everekiioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol, 2005, 50 : 297-350. (Pubitemid 40828225)
10. Sfikakis PP, Kaklamanis PH, Elezoglou A, et ai. Infliximab for recurrent, sight-threatening ocular inflammation in AdamantiadesBehcet disease. Ann Intern Med, 2004, 1 4040-4406.
11. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractoiy uveoretinitis. J Rheumatol, 2004, 31: 1362-1368. (Pubitemid 38879203)
12. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine, 2008, 87 : 345-364.
13. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease; a double blind, placebo controlled study. J Rheumatol, 2005, 32 : 98-105. (Pubitemid 40092599)
14. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology, 2006, 45 : 982-989. (Pubitemid 44283053)
15. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol, 2007, 51 : 191-196. (Pubitemid 46889493)
16. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with die combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum, 2005, 52 : 2478-2484. (Pubitemid 41117435)